Tafalgie Therapeutics appoints Tanja Ouimet to its Supervisory Board
Tafalgie Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of non-opioid pain-relieving peptides with a novel mechanism of action, announces the appointment of Tanja Ouimet,
PhD, as a member of the Supervisory Board. This appointment, effective September 26, 2024, marks a strategic milestone for the company.
With over 20 years’ experience in the pharmaceutical and biotechnology industries, Tanja Ouimet has recognized expertise in clinical and preclinical development, particularly in the fields of the central nervous system and ophthalmology. Her mission will be to accompany the company in its strategic orientations and to support the clinical advancement of its new treatments for acute and chronic pain.
“I’m delighted to be joining the Supervisory Board of
said Tanja Ouimet
Tafalgie Therapeutics, and to be working with an exceptional team to develop revolutionary therapeutic solutions capable of preventing and relieving pain without the risk of dependence or serious side effects»
“Patients suffering from acute or chronic pain are often faced with a lack of safe and effective treatments, representing a major unmet medical need. Supporting the development of a new class of innovative pain-relieving peptides is an exciting opportunity, and I look forward to making my contribution to turning these challenges into concrete solutions.»
Tanja holds a PhD in neurobiology from the Université de Montréal and completed a post-doctorate at INSERM in Paris. She has held senior positions at Pharmaleads, where she led clinical and strategic projects, and spearheaded the signature of two major licensing agreements with a combined value of over €100 million.
With a PhD in neurobiology from the Université de Montréal and a post-doctorate at INSERM in Paris, Tanja Ouimet has held senior positions at Pharmaleads. There, she led clinical and strategic projects, including the signing of two licensing agreements worth over 100 million euros. As a specialist in strategic management and clinical development, she designed trial plans, supervised regulatory submissions, and achieved measurable results such as accelerated clinical entry for several innovative molecules. Her experience also covers the search for non-dilutive financing and the development of strategic partnerships contributing to the growth of the companies she has supported.
“I am honored and excited to be able to work with such a high-level expert as Tanja, who has extensive knowledge in innovative therapy development and operational excellence, including her highly relevant expertise in the pain field»
said Aziz Moqrich, Chief Scientific Officer
“As we build momentum to successfully enter clinical trials, Tanja’s considerable experience will be a remarkable complement to the great expertise of our scientific and clinical teams” “On behalf of the Tafalgie team, I
said Eric Schettini President of Tafalgie Therapeutics.
welcome her to our Supervisory Board.»